Search
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. … [L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote
Etafedrine
go.drugbank.com/drugs/DB11587ApprovedThis belongs to the family of medications called _decongestants_. It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6]. … It was previously available as both the free base and as the hydrochloride salt manufactured by Sanofi-Aventis (now Sanofi) has been discontinued [L2563].
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after
Mixtures: MADOPAR 125 T, MADOPAR 125 TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Antidepressive Agents Indicated for DepressionOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaSynonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHIsosorbide mononitrate
go.drugbank.com/drugs/DB01020ApprovedInvestigationalIt is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. … [T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies.
Mirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalFactor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. … It is commonly marketed as Elocta or Eloctate for intravenous injection.
Lice of the body
go.drugbank.com/conditions/DBCOND0024507Drugs: Piperonyl butoxideSynonyms: Pediculosis due to Pediculus humanus corporis